Aignostics
Berlin, Germany · Artificial Intelligence, Biotechnology, Health Care
Aignostics is an artificial intelligence (AI) company that transforms complex multimodal pathology data into valuable insights. By leveraging proprietary multimodal clinical data and rigorous scientific methods, Aignostics develops innovative products and services for precision medicine. The company collaborates with biopharmaceutical partners to support drug discovery and development. Established
Key facts
- Headquarters
- Berlin, Germany
- Employees
- 117
- Industries
- Artificial Intelligence, Biotechnology, Health Care
- Status
- Private
- Website
- www.aignostics.com
- Company page
Recent activity at Aignostics
- : Aignostics has launched PathoSearch, a visual search engine for pathology cases aimed at assisting pathologists in diagnosing complex cases.
- : Aignostics has launched Atlas H&E-TME, an AI-powered application for tumor microenvironment profiling aimed at biopharma researchers.
- : Aignostics Launches New Pathology Foundation Model in Collaboration with Mayo Clinic for Enhanced Performance in Healthcare.
- : Aignostics raised $34 million in a Series B funding round led by ATHOS to enhance precision medicine with AI through new product offerings and US expansion.
Aignostics funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2024 | Series B | $34.0M |
Leadership
- Maximilian Alber, Chief Technology Officer
- Viktor Matyas, Chief Financial Officer
Verified email and direct lines for Aignostics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Aignostics in the news
- Aignostics Launches PathoSearch, a Visual Search Engine for Pathology Cases - PR Newswire (Sep 12, 2026)
- Point-of-Care Diagnostics Market Companies, Size & Trends 2026-2035 - Precedence Research (Sep 10, 2026)
- Point of Care Diagnostics Market Size, Share, Forecast, 2034 - Fortune Business Insights (Oct 12, 2026)
- Abbott statement on cyber incident in Cancer Diagnostics business - Abbott (Jul 16, 2026)
- How AI is improving cancer diagnostics - Nature (Mar 25, 2020)
- Bayer and Aignostics to collaborate on next generation precision oncology - Bayer (Mar 14, 2024)
- Veterinary Diagnostics Market Share | Industry Report [2034] - Fortune Business Insights (Oct 19, 2026)
- TAG’s 2025 Pipeline Report: TB diagnostics - European AIDS Treatment Group (Nov 20, 2025)
Companies similar to Aignostics
- Pharos · Artificial Intelligence, Biotechnology, Health Care, Health Diagnostics, Machine Learning
- Carta Healthcare · Artificial Intelligence, Biotechnology, Health Care, Health Diagnostics, Machine Learning
- Pathos AI · Artificial Intelligence, Biotechnology, Health Care, Health Diagnostics, Machine Learning
- Andor Health and Psynergy Health · Artificial Intelligence, Biotechnology, Health Care, Health Diagnostics, Machine Learning
- Lumonus · Artificial Intelligence, Biotechnology, Health Care, Health Diagnostics, Machine Learning
About Aignostics: questions and answers
What does Aignostics do?
Aignostics is an artificial intelligence (AI) company that transforms complex multimodal pathology data into valuable insights. By leveraging proprietary multimodal clinical data and rigorous scientific methods, Aignostics develops innovative products and services for precision medicine. The company collaborates with biopharmaceutical partners to support drug discovery and development. Established
Where is Aignostics headquartered?
Aignostics is headquartered in Berlin, Germany.
How many employees does Aignostics have?
Aignostics has about 117 employees.
Has Aignostics raised funding?
Yes. Fundz has recorded 1 funding event for Aignostics. The most recent, Series B of $34.0M, was in Oct 2024.
What is the latest news on Aignostics?
On Sep 12, 2026, Aignostics has launched PathoSearch, a visual search engine for pathology cases aimed at assisting pathologists in diagnosing complex cases.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy